GILL SIMBA 4
4 · Evelo Biosciences, Inc. · Filed Aug 9, 2023
Insider Transaction Report
Form 4
GILL SIMBA
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Restricted Stock Units
2023-08-07−1,171→ 16,408 total→ Common Stock (1,171 underlying) - Sale
Common Stock
2023-08-08$9.51/sh−342$3,252→ 3,754 total - Exercise/Conversion
Common Stock
2023-08-07+1,171→ 4,096 total
Footnotes (4)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
- [F2]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person on December 7, 2022, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
- [F3]The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices within the range of $9.08 to $9.55, inclusive. The reporting person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
- [F4]The RSUs vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date.